Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea (EPRICOD)
This research aims to improve our knowledge of the epidemiology of patients consulting in the COvid-19 Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID-19 affects France and impacts its health system. The reception of all intermediate patients will be on the Emergency Structures (SU). Indeed, the French healthcare system centralizes unscheduled urgent care on the ER. The aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to SU or the diagnostic approach to respiratory difficulty may be carried out.
A central issue of this diagnostic strategy will be to be rapid, since the diagnosis will have to be made in the context of significant flows, with a need to quickly refer patients to the most suitable downstream service, while limiting the risk contamination of caregivers and vulnerable patients if a COVID-19 + patient is admitted to an unsuitable service. However, virological tests do not currently allow rapid results for COVID-19.
Research project of investigatory aims to develop a predictive model of the risk of being COVID-19 positive for patients admitted to the emergency room for acute dyspnea.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Toulouse、法国、31000
- University Hospital of Toulouse
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- All patients over 15 years admitted to the RECOP unit for dyspnea
Exclusion Criteria:
- Patient admitted to shock for respiratory distress requiring immediate respiratory support.
- Patient under justice safeguard
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
RECOP unit patient
All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree.
Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
|
All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree.
Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea
大体时间:inclusion day
|
demographic variables, usual history and treatments, episode characteristics (symptomatology, evolution, treatment taken) and data from the initial clinical examination will be collected by doctor
|
inclusion day
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
病毒学状况
大体时间:30天
|
将通过电话向患者收集病毒学状态
|
30天
|
死亡率状况
大体时间:30天
|
将通过电话向患者收集死亡率状况
|
30天
|
Describe the characteristics of patients admitted to reCOP units according to their virological status
大体时间:30 days
|
The COVID-19 virological condition will be taken with PCR tests on naso-pharyngeal samples or on sputum for patients taking
|
30 days
|
合作者和调查者
调查人员
- 首席研究员:Paul-Henri Auboiroux, MD、University Hospital of Toulouse
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
RECOP unit patient的临床试验
-
Sykehuset i Vestfold HFHospital Pharmacy Enterprise, South Eastern Norway完全的
-
Brigham and Women's HospitalGordon and Betty Moore Foundation完全的
-
Brigham and Women's HospitalPatient-Centered Outcomes Research Institute主动,不招人
-
Dana-Farber Cancer Institute邀请报名
-
Ohio State University Comprehensive Cancer CenterAmerican Cancer Society, Inc.完全的
-
Columbia UniversityNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University of California, Los... 和其他合作者完全的
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)完全的